

Proteomics Market by Product (Spectroscopy, Chromatography, Electrophoresis, X-Ray Crystallography), Reagent, Service (Core Proteomics, Bioinformatics), Application (Diagnostic, Drug Discovery), End User (Hospital, Biopharma) - Global Forecast to 2030

Market Report | 2026-01-27 | 983 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global proteomics market is projected to reach USD 65.78 billion by 2030 from USD 36.32 billion in 2025, at a CAGR of 12.6% from 2025 to 2030. Rising use of proteomics in oncology, immunology and other complex diseases is pushing higher routine demand for protein profiling across global labs. Pharma and biotech teams are expanding biomarker programs and running larger translational cohorts, which increases throughput needs for LC-MS workflows, targeted panels, and standardized sample preparation.

<https://mnmimg.marketsandmarkets.com/Images/proteomics-market-img-overview.webp>

□

"The immunoassay reagents segment accounted for the largest share by reagent in the proteomics market in 2024"

Based on reagent, the proteomics market is segmented into, protein microarray reagents, spectroscopy reagents, X-ray crystallography reagents, chromatography reagents, electrophoresis reagents, immunoassay reagents, and protein fractionation reagents. The immunoassay reagents dominated the reagent segment; however spectroscopy reagent is anticipated to grow at significant CAGR during the forecast period. Factors like growing use of mass spectrometry-based techniques, development of high-throughput mass spectrometry techniques, increasing interest in personalized medicine and biomarker discovery are likely to drive the segmental growth.

?

"The biopharmaceutical companies segment accounted for the largest share by end user segment in the proteomics market in

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2024"

Based on end user, the proteomics market is segmented into hospitals, clinical laboratories, biopharmaceutical companies, academic & research institutes, and other end users. The biopharmaceutical companies segment dominated the proteomics market owing to the rising focus of pharma giants on core activities like increasing R&D for the discovery and development of new molecules.

"The Asia Pacific region is growing at the highest CAGR in the proteomics market from 2025 to 2030."

Geographically, the proteomics market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. In 2023, North America accounted for the major share of the proteomics market. The Asia Pacific region is likely to grow at significant CAGR during the forecast period owing to various factors such as growing fields of proteomics and genomics research in conjunction with an increase in funding toward research studies. Rising investment by biopharmaceutical companies, growing research activity in the area of mAb-based therapeutics are likely to drive market expansion in the region.

The primary interviews conducted for this report can be categorized as follows:

- By Company Type: Tier 1- 40%, Tier 2- 30% and Tier 3- 30%
- By Designation: Directors- 20%, Managers- 10% and Others - 70%,
- By Region: North America -35%, Europe -25%, Asia-Pacific -25%, Latin America -10%, and Middle East -5%.

List of Companies Profiled in the Report:

- Thermo fisher Scientific Inc (US)
- Agilent Technologies, Inc. (US)
- Merck KGaA (Germany)
- Danaher Corporation (US)
- Waters Corporation (US)
- Bio-Rad Laboratories, Inc. (US)
- Bruker Corporation (US)
- Revvity (US)
- Shimadzu Corporation (Japan)
- Illumina Inc (US)
- Promega Corporation (US)
- Eurofins Scientific (Luxembourg)
- Qiagen (Netherlands)
- Charles River Laboratories (US)
- Protagene (Germany)
- Creative Proteomics (US)
- Horiba (Japan)
- Sengenics Corporation LLC (US)
- Labvantage-Biomax GmbH (Germany)
- Cell Signaling Technology, Inc. (US)
- FIOS Genomics (UK)
- Azenta Life Sciences (US)
- Medgenome (India)
- Biognosys AG (Switzerland)
- Macrogen Inc (South Korea)

Research Coverage:

This research report categorizes the proteomics market by Instrumentation Technology : Spectroscopy (Mass spectroscopy, NMR

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

spectroscopy, CD spectroscopy), Chromatography (High performance liquid chromatography, Ion chromatography, Affinity chromatography, Supercritical fluid chromatography), Electrophoresis (Gel electrophoresis, Capillary electrophoresis), Protein Microarrays (Biochips, Microarray instruments), X ray Crystallography, Surface Plasmon Resonance , Protein fractionation, Other instrumentation technologies; by reagent: Immunoassay reagents, spectroscopy reagents, chromatography reagents, protein microarray reagents, X?ray crystallography reagents, electrophoresis reagents, protein fractionation reagents, other reagents; by Service: Core proteomics services (Protein identification services, Quantitative proteomics services, Protein characterization services, Protein purification services, Protein separation services, Protein sequencing services, Custom assay services), Bioinformatics services; by software: Bioinformatics Tools, Bioinformatics databases; by Application: Clinical Diagnostics (Cancer, Infectious diseases, Diabetes, Neurological disorders, Autoimmune diseases, Cardiovascular diseases, Other clinical diagnostic applications), Drug discovery & Development (Target discovery, Lead identification, Lead optimization, Preclinical studies), Other applications; by End User: Biopharmaceutical Companies, Academic Institutes & Research Institutes, Hospitals, Clinical laboratories, Other end users and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints, influencing the growth of the proteomics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product portfolio, key strategies such as product launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the proteomics market. Competitive analysis of top players and upcoming startups in the proteomics market ecosystem is covered in this report.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall proteomics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Strong pull from oncology and proteogenomics programs, Growth in multi-omics), restraints (High total cost of ownership), opportunities (Single-cell and low-input proteomics, Cloud and shared data platforms to accelerate discovery), and challenges (Data volume, interpretation and bioinformatics bottlenecks) influencing the growth of the market.

- Product Development/Innovation: Detailed insights on newly launched products and services of the proteomics market
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the proteomics market
- Competitive Assessment: Thermo Fisher Scientific, Inc. (US), Danaher Corporation (US), Agilent Technologies, Inc. (US), Bio?Rad Laboratories (US), Revvity (US), Illumina Inc. (US), Promega Corporation (US) and Charles River Laboratories (US), among others.

Table of Contents:

1	INTRODUCTION	78
1.1	STUDY OBJECTIVES	78
1.2	MARKET DEFINITION	78
1.3	STUDY SCOPE	78
1.3.1	MARKET SEGMENTATION AND REGIONS COVERED	79
1.3.2	INCLUSIONS & EXCLUSIONS	80
1.3.3	YEARS CONSIDERED	81
1.3.4	CURRENCY CONSIDERED	81
1.4	STAKEHOLDERS	82
1.5	SUMMARY OF CHANGES	82
2	EXECUTIVE SUMMARY	83
2.1	MARKET HIGHLIGHTS AND KEY INSIGHTS	83

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.2	KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS	84
2.3	DISRUPTIVE TRENDS IN PROTEOMICS MARKET	85
2.4	HIGH-GROWTH SEGMENTS	86
2.5	REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST	87
3	PREMIUM INSIGHTS	88
3.1	PROTEOMICS MARKET OVERVIEW	88
3.2	NORTH AMERICA: PROTEOMICS MARKET, BY SERVICE	89
3.3	PROTEOMICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	89
3.4	PROTEOMICS MARKET SHARE, BY APPLICATION, 2026 VS 2031 (%)	90
4	MARKET OVERVIEW	91
4.1	INTRODUCTION	91
4.2	MARKET DYNAMICS	92
4.2.1	DRIVERS	93
4.2.1.1	Advancements in DIA and high-throughput mass spectrometry	93
4.2.1.2	Growing clinical and plasma proteomics adoption for biomarker discovery and translational diagnostics	93
4.2.1.3	Rising integration of proteomics with multi-omics workflows	94
4.2.1.4	Expansion of automation and low-input proteomics workflows	94
4.2.2	RESTRAINTS	94
4.2.2.1	High capital intensity of high-resolution mass spectrometry platforms	94
4.2.2.2	Complexity of proteomics data analysis	95
4.2.3	OPPORTUNITIES	95
4.2.3.1	Emergence of single-cell proteomics for high-resolution cellular profiling	95
4.2.3.2	Expansion of spatial proteomics in tissue-context biology and biomarker research	95
4.2.3.3	Adoption of AI-enabled proteomics informatics	96
4.2.4	CHALLENGES	96
4.2.4.1	Limited detection of low-abundance proteins	96
4.2.4.2	Lack of standardization across workflows	97
4.3	UNMET NEEDS AND WHITE SPACES	97
4.4	INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES	98
4.5	STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS	99
5	INDUSTRY TRENDS	100
5.1	PORTER'S FIVE FORCES ANALYSIS	100
5.1.1	INTENSITY OF COMPETITIVE RIVALRY	101
5.1.2	BARGAINING POWER OF SUPPLIERS	101
5.1.3	BARGAINING POWER OF BUYERS	101
5.1.4	THREAT OF SUBSTITUTES	101
5.1.5	THREAT OF NEW ENTRANTS	101
5.2	MACROECONOMIC OUTLOOK	102
5.2.1	INTRODUCTION	102
5.2.2	GDP TRENDS AND FORECAST	102
5.2.3	TRENDS IN GLOBAL HEALTHCARE INDUSTRY	102
5.2.4	TRENDS IN GLOBAL BIOTECH INDUSTRY	103
5.3	VALUE CHAIN ANALYSIS	104
5.4	ECOSYSTEM ANALYSIS	105
5.4.1	ROLE OF PLAYERS IN ECOSYSTEM	106
5.5	PRICING ANALYSIS	107
5.5.1	AVERAGE SELLING PRICE TREND, KEY PLAYER, 2023-2025	108

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.5.1.1	Instrumentation	108
5.5.1.2	Reagents	109
5.5.2	AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025	109
5.5.2.1	Instrumentation	109
5.5.3	REAGENTS	110
5.6	TRADE ANALYSIS	111
5.6.1	IMPORT SCENARIO (HS CODE 9027.20)	111
5.6.2	EXPORT SCENARIO (HS CODE 9027.20)	112
5.6.3	IMPORT SCENARIO (HS CODE 9027.81)	112
5.6.4	EXPORT SCENARIO (HS CODE 9027.81)	113
5.7	KEY CONFERENCES & EVENTS, 2026-2027	114
5.8	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	114
5.9	INVESTMENT & FUNDING SCENARIO	115
	?	
5.10	CASE STUDY ANALYSIS	116
5.10.1	PLASMA PROTEOMICS IMPROVES RISK PREDICTION ACROSS MULTIPLE DISEASES	116
5.10.2	PLASMA PROTEOMICS SUPPORTS ALS BIOMARKER DISCOVERY	116
5.10.3	AI-ENABLED PROTEOMICS ADVANCES DEMENTIA DIAGNOSTICS	117
5.11	IMPACT OF US TARIFF-PROTEOMICS MARKET	117
5.11.1	INTRODUCTION	117
5.11.2	KEY TARIFF RATES	117
5.11.3	PRICE IMPACT ANALYSIS	118
5.11.4	IMPACT ON COUNTRIES/REGIONS	119
5.11.4.1	US	119
5.11.4.2	Europe	119
5.11.4.3	Asia Pacific	120
5.11.5	IMPACT ON END-USE INDUSTRIES	120
5.11.5.1	Hospitals	120
5.11.5.2	Clinical laboratories	120
5.11.5.3	Biopharmaceutical companies	121
5.11.5.4	Academic & research institutes	121
6	SUSTAINABILITY AND REGULATORY LANDSCAPE	122
6.1	REGIONAL REGULATIONS AND COMPLIANCE	122
6.1.1	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	122
6.1.2	INDUSTRY STANDARDS	125
6.1.2.1	North America	125
6.1.2.2	Europe	125
6.1.2.3	Asia Pacific	126
6.1.2.4	Rest of the world	126
6.2	SUSTAINABILITY INITIATIVES	126
6.3	IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES	127
6.4	CERTIFICATIONS, LABELING, ECO-STANDARDS	127
7	TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS	129
7.1	KEY TECHNOLOGIES	129
7.1.1	MASS SPECTROMETRY	129
7.1.1.1	Intact/top-down protein analysis	129
7.1.1.2	Chromatography	130

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7.1.1.3	Bioinformatics tools	130
7.1.1.4	Protein microarrays	130
	?	
7.2	COMPLEMENTARY TECHNOLOGIES	131
7.2.1	TRANSCRIPTOMICS	131
7.2.2	METABOLOMICS	131
7.2.3	SINGLE-CELL PROTEOMICS	131
7.3	ADJACENT TECHNOLOGIES	132
7.3.1	AI-DRIVEN PROTEOMICS DATA ANALYSIS	132
7.3.2	AI-DRIVEN PROTEIN STRUCTURE & FUNCTION PREDICTION	132
7.4	TECHNOLOGY ROADMAP	132
7.5	PATENT ANALYSIS	133
7.5.1	METHODOLOGY	133
7.5.2	NUMBER OF PATENTS FILED, BY DOCUMENT TYPE	133
7.5.3	LIST OF KEY PATENTS	134
7.6	FUTURE APPLICATIONS	135
7.7	IMPACT OF AI/GEN AI ON PROTEOMICS MARKET	136
7.7.1	TOP USE CASES AND MARKET POTENTIAL	137
7.7.2	BEST PRACTICES IN AI-ENABLED PROTEOMICS WORKFLOWS	137
7.7.3	CASE STUDIES OF AI IMPLEMENTATION IN PROTEOMICS MARKET	137
7.7.4	INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS	138
7.7.5	CLIENTS' READINESS TO ADOPT GENERATIVE AI IN PROTEOMICS MARKET	138
8	CUSTOMER LANDSCAPE & BUYER BEHAVIOR	140
8.1	DECISION-MAKING PROCESS	140
8.2	BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA	140
8.2.1	KEY STAKEHOLDERS IN BUYING PROCESS	140
8.2.2	KEY BUYING CRITERIA, BY END USER	141
8.3	ADOPTION BARRIERS & INTERNAL CHALLENGES	142
8.4	UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES	143
9	PROTEOMICS MARKET, BY OFFERING	144
9.1	INTRODUCTION	145
9.2	INSTRUMENTS	145
9.2.1	HIGH-SENSITIVITY AND AUTOMATED PROTEOMICS INSTRUMENT TO DRIVE MARKET GROWTH	145
9.3	REAGENTS & CONSUMABLES	149
9.3.1	SCALABLE MULTIPLEX ASSAYS AND WORKFLOW-READY CONSUMABLES TO DRIVE MARKET	149
9.4	SOFTWARE	152
9.4.1	AI-ENABLED CLOUD-CONNECTED SOFTWARE TO DRIVE MARKET GROWTH	152
9.5	SERVICES	156
9.5.1	OUTSOURCED EXPERTISE AND SCALABLE LC-MS/MS CAPACITY TO DRIVE MARKET	156
	?	
10	PROTEOMICS MARKET, BY REAGENTS & CONSUMABLES	160
10.1	INTRODUCTION	161
10.2	IMMUNOASSAY REAGENTS & CONSUMABLES	161
10.2.1	ANTIBODIES & HIGH-AFFINITY BINDERS	165
10.2.1.1	Validated high-affinity binders to aid market growth	165
10.2.2	ASSAY KITS	169
10.2.2.1	Prevalidated assay kits to accelerate market growth	169

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.2.3	OTHER IMMUNOASSAY REAGENTS & CONSUMABLES	172
10.3	SPECTROSCOPY REAGENTS & CONSUMABLES	176
10.3.1	MASS TAGGING & LABELING KITS	180
10.3.1.1	Multiplexed protein quantification to aid market growth	180
10.3.2	ENZYMES	183
10.3.2.1	Automation-ready digestion enzymes to drive market growth	183
10.3.3	OTHER SPECTROSCOPY REAGENTS & CONSUMABLES	186
10.4	CHROMATOGRAPHY REAGENTS & CONSUMABLES	189
10.4.1	ANALYTICAL COLUMNS	193
10.4.1.1	High-sensitivity microflow and bio-inert columns to support market growth	193
10.4.2	REAGENTS	196
10.4.2.1	High-purity and method-compatible solvents to support market growth	196
10.4.3	OTHER CHROMATOGRAPHY REAGENTS & CONSUMABLES	199
10.5	PROTEIN MICROARRAY REAGENTS & CONSUMABLES	202
10.5.1	BIOCHIPS	206
10.5.1.1	Miniaturized, functionalized biochips to drive market growth	206
10.5.1.2	Lab-on-chips	210
10.5.1.2.1	Integrated microfluidic chips to propel market growth	210
10.5.1.3	Protein chips	213
10.5.1.3.1	Functional protein chips are converting biomarker and interaction discovery into scalable multiplex assays to aid market growth	213
10.5.2	DETECTION REAGENTS	217
10.5.2.1	Brighter, lower-background detection chemistries to propel market growth	217
10.6	X-RAY CRYSTALLOGRAPHY REAGENTS & CONSUMABLES	220
10.6.1	CRYSTALLIZATION SCREENS	224
10.6.1.1	Automated high-throughput screening to drive market growth	224
10.6.2	OTHER X-RAY CRYSTALLOGRAPHY REAGENTS & CONSUMABLES	228
10.7	ELECTROPHORESIS REAGENTS & CONSUMABLES	231
10.7.1	ELECTROPHORESIS STAINS & DYES	235
10.7.1.1	High-sensitivity and MS-compatible stains to improve protein visualization	235
10.7.2	OTHER ELECTROPHORESIS REAGENTS & CONSUMABLES	238
10.8	PROTEIN FRACTIONATION REAGENTS & CONSUMABLES	242
10.8.1	PROTEIN FRACTIONATION & ENRICHMENT KITS	245
10.8.1.1	Automated enrichment kits to drive market growth	245
10.8.2	OTHER PROTEIN FRACTIONATION REAGENTS & CONSUMABLES	249
10.9	OTHER REAGENTS & CONSUMABLES	253
11	PROTEOMICS MARKET, BY INSTRUMENTATION TECHNOLOGY	257
11.1	INTRODUCTION	258
11.2	SPECTROSCOPY	258
11.2.1	MASS SPECTROMETRY	262
11.2.1.1	High specificity and technological advancements to propel segment growth	262
11.2.2	NMR SPECTROSCOPY	266
11.2.2.1	Accurate evaluation of physical, chemical, electronic, and structural information of proteins to aid segment growth	266
11.2.3	CD SPECTROSCOPY	270
11.2.3.1	Non-destructive and non-invasive techniques to examine changes in secondary protein structures	270
11.3	CHROMATOGRAPHY	273
11.3.1	HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY	277

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.3.1.1 High resolution, sensitivity, and reproducibility to spur segment growth 277
- 11.3.2 ION CHROMATOGRAPHY 280
- 11.3.2.1 High resolving power, simplicity, and controllability to separate and purify proteins 280
- 11.3.3 AFFINITY CHROMATOGRAPHY 284
- 11.3.3.1 High specificity for target proteins and easy identification of novel protein interactions to drive segment 284
- 11.3.4 SUPERCRITICAL FLUID CHROMATOGRAPHY 287
- 11.3.4.1 Ability to separate complex protein mixtures with high efficiency and speed to fuel segment growth 287
- 11.4 ELECTROPHORESIS 291
- 11.4.1 GEL ELECTROPHORESIS 295
- 11.4.1.1 Increasing demand for proteomics research and personalized medicine to boost segment growth 295
- 11.4.2 CAPILLARY ELECTROPHORESIS 298
- 11.4.2.1 Low diffusion coefficients of biomolecules and easy elimination of sample carryover between measurements to drive market 298
- 11.5 PROTEIN MICROARRAYS 302
- 11.5.1 INTEGRATED SYSTEMS 306
- 11.5.1.1 Integrated systems to enable high-throughput and reproducible analysis of proteins 306
- 11.5.2 MICROARRAY SCANNERS 309
- 11.5.2.1 Cost-effective and high-quality analysis to propel segment growth 309
- ?
- 11.5.3 ARRAYERS 313
- 11.5.3.1 Technological advancements to drive adoption of arrayers in large-scale projects 313
- 11.6 X-RAY CRYSTALLOGRAPHY 316
- 11.6.1 RISING NEED FOR HIGH-RESOLUTION INFORMATION ON PROTEIN STRUCTURES TO AUGMENT MARKET GROWTH 316
- 11.7 SURFACE PLASMON RESONANCE 319
- 11.7.1 INCREASING ABILITY TO BIND AFFINITIES AND KINETICS OF COMPLEXES TO PROPEL MARKET GROWTH 319
- 11.8 PROTEIN FRACTIONATION 323
- 11.8.1 PROTEIN FRACTIONATION TO ENABLE EFFECTIVE SEPARATION OF PROTEINS IN COMPLEX MIXTURES 323
- 11.9 OTHER INSTRUMENTATION TECHNOLOGIES 326
- 12 PROTEOMICS MARKET, BY SERVICE 330
- 12.1 INTRODUCTION 331
- 12.2 CORE PROTEOMICS SERVICES 331
- 12.2.1 PROTEIN IDENTIFICATION SERVICES 335
- 12.2.1.1 Outsourced mass spectrometry and complex-sample workflows to boost market growth 335
- 12.2.2 QUANTITATIVE PROTEOMICS SERVICES 339
- 12.2.2.1 Quantified protein profiling and translational model validation to drive market growth 339
- 12.2.3 PROTEIN CHARACTERIZATION SERVICES 342
- 12.2.3.1 Biologics complexity and comparability testing to drive market growth 342
- 12.2.4 PROTEIN PURIFICATION SERVICES 346
- 12.2.4.1 High-purity biologics and outsourced purification expertise to drive market 346
- 12.2.5 PROTEIN SEPARATION SERVICES 349
- 12.2.5.1 Complex sample analysis and biomarker research to augment segment growth 349
- 12.2.6 PROTEIN SEQUENCING SERVICES 353
- 12.2.6.1 Antibody development and outsourced sequence interpretation to drive market 353
- 12.2.7 CUSTOM ASSAY SERVICES 356
- 12.2.7.1 Biomarker specificity and outsourced assay design to drive market 356
- 12.3 BIOINFORMATICS SERVICES 360
- 12.3.1 SCALABLE DATA INTERPRETATION AND MULTI-OMICS INTEGRATION TO SPUR MARKET GROWTH 360

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

?

13 □ PROTEOMICS MARKET, BY SOFTWARE □ 364

13.1 □ INTRODUCTION □ 365

13.2 □ BIOINFORMATICS TOOLS □ 365

13.2.1 □ RISING DATA COMPLEXITY AND AI-ENABLED ANALYSIS TO AUGMENT MARKET GROWTH □ 365

13.3 □ BIOINFORMATICS DATABASES □ 369

13.3.1 □ EXPANDING CURATED PROTEIN KNOWLEDGEBASES AND MULTI-OMICS INTEGRATION TO DRIVE MARKET □ 369

14 □ PROTEOMICS MARKET, BY WORKFLOW □ 373

14.1 □ INTRODUCTION □ 374

14.2 □ SAMPLE PREPARATION □ 374

14.2.1 □ AUTOMATION, REPRODUCIBILITY, AND HIGH-THROUGHPUT BIOMARKER WORKFLOWS TO AUGMENT MARKET GROWTH □ 374

14.3 □ PROTEIN SEPARATION & FRACTIONATION □ 378

14.3.1 □ RISING DEMAND FOR DEEPER PROTEOME COVERAGE AND IMPROVED LC-MS SENSITIVITY TO DRIVE MARKET □ 378

14.4 □ PROTEIN IDENTIFICATION & QUANTIFICATION □ 381

14.4.1 □ HIGHER SENSITIVITY, DEEPER PROTEOME COVERAGE, AND SCALABLE QUANTIFICATION WORKFLOWS TO AUGMENT MARKET GROWTH □ 381

14.5 □ PROTEIN CHARACTERIZATION & STRUCTURAL ANALYSIS □ 385

14.5.1 □ RISING BIOLOGICS COMPLEXITY AND DEMAND FOR STRUCTURE-FUNCTION INSIGHTS TO DRIVE MARKET □ 385

14.6 □ BIOINFORMATICS & DATA ANALYSIS □ 388

14.6.1 □ RISING DATA COMPLEXITY, DIA ADOPTION, AND AI-ENABLED INTERPRETATION TO DRIVE MARKET □ 388

15 □ PROTEOMICS MARKET, BY TYPE □ 392

15.1 □ INTRODUCTION □ 393

15.1.1 □ BULK PROTEOMICS □ 393

15.1.1.1 □ Large-cohort biomarker discovery, high-throughput protein profiling, and scalable multi-omics integration to drive market growth □ 393

15.1.2 □ TARGETED/AFFINITY PROTEOMICS □ 397

15.1.2.1 □ High-sensitivity protein panels and scalable biomarker validation to drive the market □ 397

15.1.3 □ SPATIAL PROTEOMICS □ 400

15.1.3.1 □ Emerging spatial biology workflows to drive market growth □ 400

15.1.4 □ SINGLE MOLECULE PROTEOMICS/NEXT GENERATION PROTEOMICS □ 404

15.1.4.1 □ Demand for ultra-sensitive and low-input protein analysis to drive market □ 404

?

16 □ PROTEOMICS MARKET, BY APPLICATION □ 408

16.1 □ INTRODUCTION □ 409

16.2 □ CLINICAL DIAGNOSTICS □ 409

16.2.1 □ CANCER □ 413

16.2.1.1 □ Precision oncology and high-sensitivity protein biomarker testing to propel market growth □ 413

16.2.2 □ INFECTIOUS DISEASES □ 417

16.2.2.1 □ Rapid pathogen identification to support market growth □ 417

16.2.3 □ DIABETES □ 420

16.2.3.1 □ Precision diabetes care and protein-based risk stratification to aid market growth □ 420

16.2.4 □ NEUROLOGICAL DISORDERS □ 424

16.2.4.1 □ Blood-based neuroprotein biomarkers to fuel market growth □ 424

16.2.5 □ AUTOIMMUNE DISEASES □ 427

16.2.5.1 □ Demand for immune-pathway biomarkers and flare monitoring to propel market growth □ 427

16.2.6 □ CARDIOVASCULAR DISEASES □ 431

16.2.6.1 □ Multi-protein cardiovascular risk profiling to drive growth □ 431

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.2.7 OTHER CLINICAL DIAGNOSTIC APPLICATIONS 434
- 16.3 DRUG DISCOVERY & DEVELOPMENT 438
 - 16.3.1 TARGET DISCOVERY 442
 - 16.3.1.1 High-throughput proteomics and AI-enabled target biology to support segment growth 442
 - 16.3.2 LEAD IDENTIFICATION 445
 - 16.3.2.1 Chemoproteomics and high-throughput protein profiling to propel growth 445
 - 16.3.3 LEAD OPTIMIZATION 449
 - 16.3.3.1 Need for optimizing drug efficacy and safety to spur segment growth 449
 - 16.3.4 PRECLINICAL STUDIES 452
 - 16.3.4.1 Translational safety biomarkers and pathway-level efficacy assessment to drive growth 452
- 16.4 OTHER APPLICATIONS 456
- 17 PROTEOMICS MARKET, BY END USER 460
 - 17.1 INTRODUCTION 461
 - 17.2 BIOPHARMACEUTICAL COMPANIES 461
 - 17.2.1 PRECISION MEDICINE, BIOMARKER-LED R&D, AND POPULATION-SCALE PROTEOMICS TO DRIVE MARKET 461
 - 17.3 ACADEMIC & RESEARCH INSTITUTES 465
 - 17.3.1 SHARED CORE INFRASTRUCTURE AND MULTI-OMICS RESEARCH MEDICINE TO BOOST MARKET GROWTH 465
 - 17.4 HOSPITALS 468
 - 17.4.1 PRECISION DIAGNOSTICS AND HOSPITAL-BASED TRANSLATIONAL RESEARCH TO BOOST MARKET GROWTH 468
 - 17.5 CLINICAL LABORATORIES 472
 - 17.5.1 PROTEIN-BASED DIAGNOSTICS AND LABORATORY WORKFLOW AUTOMATION TO SUPPORT MARKET GROWTH 472
 - 17.6 OTHER END USERS 475
- 18 PROTEOMICS MARKET, BY REGION 479
 - 18.1 INTRODUCTION 480
 - 18.2 NORTH AMERICA 480
 - 18.2.1 US 492
 - 18.2.1.1 Precision medicine, high-throughput platforms, and biomarker-driven drug development to drive the market growth. 492
 - 18.2.2 CANADA 503
 - 18.2.2.1 Precision oncology networks, standardized LC-MS workflows, and AI-enabled multiomics to drive the market growth 503
 - 18.3 EUROPE 514
 - 18.3.1 GERMANY 525
 - 18.3.1.1 Well-established pharmaceutical industry and increased government funding to augment market growth 525
 - 18.3.2 UK 536
 - 18.3.2.1 Population biobanks, clinical cohorts, and high-throughput multiomics to drive market growth 536
 - 18.3.3 FRANCE 547
 - 18.3.3.1 National infrastructure, clinical biomarker programs, and multiomics collaboration to drive the market growth 547
 - 18.3.4 SWITZERLAND 558
 - 18.3.4.1 Pharma-led innovation, deep plasma proteomics, and translational multiomics to drive the market growth 558
 - 18.3.5 ITALY 569
 - 18.3.5.1 Clinical multiomics, biomarker research, and cross-border proteomics collaboration to drive the market growth 569
 - 18.3.6 SPAIN 580
 - 18.3.6.1 Spatial omics infrastructure, clinical collaboration, and high-throughput proteomics to drive the market growth 580
 - 18.3.7 REST OF EUROPE 591
 - 18.4 ASIA PACIFIC 602
 - 18.4.1 CHINA 614
 - 18.4.1.1 Precision medicine investment, automated LC-MS/MS workflows, and large-scale clinical proteomics to fuel market growth 614

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 18.4.2 JAPAN 625
 - 18.4.2.1 Precision medicine, automated LC-MS/MS workflows, and clinical biomarker programs to drive market 625
- 18.4.3 INDIA 636
 - 18.4.3.1 Biopharma R&D and LC-MS/MS adoption to support market growth 636
- 18.4.4 SOUTH KOREA 647
 - 18.4.4.1 Biopharma innovation, high-plex protein profiling, and automated multiomics workflows to propel market growth 647
- 18.4.5 AUSTRALIA 658
 - 18.4.5.1 Translational biomedicine, high-resolution LC-MS/MS, and automated protein analytics to favor market growth 658
- 18.4.6 REST OF ASIA PACIFIC 669
- 18.5 LATIN AMERICA 679
 - 18.5.1 BRAZIL 690
 - 18.5.1.1 Open LC-MS/MS infrastructure and translational biomarker programs to drive market 690
 - 18.5.2 MEXICO 701
 - 18.5.2.1 Oncology biomarker research to augment market growth 701
 - 18.5.3 REST OF LATIN AMERICA 712
- 18.6 MIDDLE EAST 723
 - 18.6.1 GCC COUNTRIES 734
 - 18.6.1.1 Saudi Arabia 745
 - 18.6.1.1.1 Biotechnology localization and clinical biomarker research to boost market growth 745
 - 18.6.1.2 UAE 756
 - 18.6.1.2.1 Multiomics infrastructure and public-private research partnerships to drive market 756
 - 18.6.1.3 Rest of GCC Countries 767
 - 18.6.2 REST OF MIDDLE EAST 778
- 18.7 AFRICA 789
 - 18.7.1 BIOMARKER PLATFORM ADOPTION TO PROPEL MARKET GROWTH 789
- 19 COMPETITIVE LANDSCAPE 801
 - 19.1 INTRODUCTION 801
 - 19.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2021-2025 801
 - 19.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PROTEOMICS MARKET, JANUARY 2023-APRIL 2026 801
 - 19.3 REVENUE ANALYSIS, 2021-2025 803
 - 19.4 MARKET SHARE ANALYSIS, 2025 804
 - 19.5 BRAND COMPARISON 807
 - 19.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 808
 - 19.6.1 STARS 808
 - 19.6.2 EMERGING LEADERS 808
 - 19.6.3 PERVASIVE PLAYERS 808
 - 19.6.4 PARTICIPANTS 808
 - 19.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 810
 - 19.6.5.1 Company footprint 810
 - 19.6.5.2 Region footprint 811
 - 19.6.5.3 Instrumentation technology footprint 812
 - 19.6.5.4 Reagent footprint 813
 - 19.6.5.5 Service footprint 815
 - 19.6.5.6 Software footprint 816
 - 19.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 817
 - 19.7.1 PROGRESSIVE COMPANIES 817
 - 19.7.2 RESPONSIVE COMPANIES 817

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 19.7.3 DYNAMIC COMPANIES 817
- 19.7.4 STARTING BLOCKS 817
- 19.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 819
 - 19.7.5.1 Detailed list of key startup/SME players 819
 - 19.7.5.2 Competitive benchmarking of startups/SMEs 820
- 19.8 COMPANY VALUATION AND FINANCIAL METRICS 821
 - 19.8.1 COMPANY VALUATION 821
 - 19.8.2 FINANCIAL METRICS 822
- 19.9 COMPETITIVE SCENARIO 822
 - 19.9.1 PRODUCT LAUNCHES 822
 - 19.9.2 DEALS 823
 - 19.9.3 EXPANSIONS 824
- 20 COMPANY PROFILES 825
 - 20.1 KEY PLAYERS 825
 - 20.1.1 THERMO FISHER SCIENTIFIC INC. 825
 - 20.1.1.1 Business overview 825
 - 20.1.1.2 Products/Services/Solutions offered 826
 - 20.1.1.3 Recent developments 839
 - 20.1.1.3.1 Product launches 839
 - 20.1.1.3.2 Deals 840
 - 20.1.1.4 MnM view 840
 - 20.1.1.4.1 Key strengths 840
 - 20.1.1.4.2 Strategic choices 840
 - 20.1.1.4.3 Weaknesses and competitive threats 840
 - 20.1.2 AGILENT TECHNOLOGIES, INC. 841
 - 20.1.2.1 Business overview 841
 - 20.1.2.2 Products/Services/Solutions offered 842
 - 20.1.2.3 Recent developments 847
 - 20.1.2.3.1 Product launches 847
 - 20.1.2.3.2 Deals 848
 - 20.1.2.3.3 Expansions 849
 - 20.1.2.4 MnM view 849
 - 20.1.2.4.1 Key strengths 849
 - 20.1.2.4.2 Strategic choices 849
 - 20.1.2.4.3 Weaknesses and competitive threats 849
 - 20.1.3 MERCK KGAA 850
 - 20.1.3.1 Business overview 850
 - 20.1.3.2 Products/Services/Solutions offered 851
 - 20.1.3.3 Recent developments 854
 - 20.1.3.3.1 Deals 854
 - 20.1.3.4 MnM view 854
 - 20.1.3.4.1 Key strengths 854
 - 20.1.3.4.2 Strategic choices 854
 - 20.1.3.4.3 Weaknesses and competitive threats 854
 - 20.1.4 DANAHER CORPORATION 855
 - 20.1.4.1 Business overview 855

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 20.1.4.2 Products/Services/Solutions offered 856
- 20.1.4.3 Recent developments 868
 - 20.1.4.3.1 Product launches 868
 - 20.1.4.3.2 Deals 869
- 20.1.4.4 MnM view 869
 - 20.1.4.4.1 Key strengths 869
 - 20.1.4.4.2 Strategic choices 869
 - 20.1.4.4.3 Weaknesses and competitive threats 869
- 20.1.5 SHIMADZU CORPORATION 870
 - 20.1.5.1 Business overview 870
 - 20.1.5.2 Products/Services/Solutions offered 871
 - 20.1.5.3 Recent developments 876
 - 20.1.5.3.1 Product launches 876
 - 20.1.5.3.2 Expansions 876
 - 20.1.5.4 MnM view 877
 - 20.1.5.4.1 Key strengths 877
 - 20.1.5.4.2 Strategic choices 877
 - 20.1.5.4.3 Weaknesses and competitive threats 877
- 20.1.6 WATERS CORPORATION 878
 - 20.1.6.1 Business overview 878
 - 20.1.6.2 Products/Services/Solutions offered 879
 - 20.1.6.3 Recent developments 886
 - 20.1.6.3.1 Product launches 886
 - 20.1.6.3.2 Deals 886
- 20.1.7 BIO-RAD LABORATORIES, INC. 887
 - 20.1.7.1 Business overview 887
 - 20.1.7.2 Products/Services/Solutions offered 888
- ?
- 20.1.8 BRUKER 897
 - 20.1.8.1 Business overview 897
 - 20.1.8.2 Products/Services/Solutions offered 898
 - 20.1.8.3 Recent developments 904
 - 20.1.8.3.1 Product launches 904
 - 20.1.8.3.2 Deals 905
- 20.1.9 REVVITY 906
 - 20.1.9.1 Business overview 906
 - 20.1.9.2 Products/Services/Solutions offered 907
 - 20.1.9.3 Recent developments 910
 - 20.1.9.3.1 Product launches 910
- 20.1.10 ILLUMINA, INC. 911
 - 20.1.10.1 Business overview 911
 - 20.1.10.2 Products/Services/Solutions offered 912
 - 20.1.10.3 Recent developments 914
 - 20.1.10.3.1 Deals 914
- 20.1.11 PROMEGA CORPORATION 915
 - 20.1.11.1 Business overview 915
 - 20.1.11.2 Products/Services/Solutions offered 915

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 20.1.12 EUROFINS SCIENTIFIC 919
 - 20.1.12.1 Business overview 919
 - 20.1.12.2 Products/Services/Solutions offered 920
 - 20.1.12.3 Recent developments 921
 - 20.1.12.3.1 Deals 921
- 20.1.13 QIAGEN 922
 - 20.1.13.1 Business overview 922
 - 20.1.13.2 Products/Services/Solutions offered 923
 - 20.1.13.3 Recent developments 926
 - 20.1.13.3.1 Product launches 926
 - 20.1.13.3.2 Deals 927
- 20.1.14 CHARLES RIVER LABORATORIES 928
 - 20.1.14.1 Business overview 928
 - 20.1.14.2 Products/Services/Solutions offered 929
 - 20.1.14.3 Recent developments 931
 - 20.1.14.3.1 Product launches 931
 - 20.1.14.3.2 Deals 932
- 20.1.15 PROTAGENE 933
 - 20.1.15.1 Business overview 933
 - 20.1.15.2 Products/Services/Solutions offered 933
- 20.1.16 BIO-TECHNE 936
 - 20.1.16.1 Business overview 936
 - 20.1.16.2 Products/Services/Solutions offered 937
- 20.1.17 AZENTA US INC. 939
 - 20.1.17.1 Business overview 939
 - 20.1.17.2 Products/Services/Solutions offered 940
- 20.1.18 QUANTERIX 941
 - 20.1.18.1 Business overview 941
 - 20.1.18.2 Products/Services/Solutions offered 942
- 20.1.19 PROTEOMICS INTERNATIONAL 943
 - 20.1.19.1 Business overview 943
 - 20.1.19.2 Products/Services/Solutions offered 944
- 20.1.20 HAMILTON COMPANY 945
 - 20.1.20.1 Business overview 945
 - 20.1.20.2 Products/Services/Solutions offered 945
 - 20.1.20.3 Recent developments 946
 - 20.1.20.3.1 Product launches 946
- 20.2 OTHER PLAYERS 947
 - 20.2.1 CREATIVE PROTEOMICS 947
 - 20.2.2 HORIBA, LTD. 949
 - 20.2.3 LABVANTAGE-BIOMAX GMBH 950
 - 20.2.4 FIOS GENOMICS 951
 - 20.2.5 MEDGENOME 952
 - 20.2.6 BIOGNOSYS AG 953
 - 20.2.7 MACROGEN, INC. 954
 - 20.2.8 CELL SIGNALING TECHNOLOGY, INC. 955
 - 20.2.9 STANDARD BIOTOOLS 956

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 20.2.10 PIXELGEN TECHNOLOGIES 957
- 20.2.11 APPLIED BIOMICS 957
- 20.2.12 QUANTUM-SI INCORPORATED 958
- 20.2.13 ERISYON INC. 959
- 20.2.14 NAUTILUS BIOTECHNOLOGY, INC. 960
- 21 RESEARCH METHODOLOGY 961
- 21.1 RESEARCH DATA 961
- 21.1.1 SECONDARY DATA 961
- 21.1.1.1 Key data from secondary sources 961
- 21.1.2 PRIMARY DATA 962
- 21.1.2.1 Key data from primary sources 962
- 21.1.2.2 Key primary participants 963
- 21.1.2.3 Breakdown of primary interviews 963
- 21.1.2.4 Key industry insights 964
- 21.2 MARKET SIZE ESTIMATION 965
- 21.2.1 GLOBAL PROTEOMICS MARKET ESTIMATION, 2025 965
- 21.2.2 SEGMENTAL MARKET SIZE ESTIMATION 967
- 21.3 MARKET GROWTH RATE PROJECTIONS 969
- 21.4 DATA TRIANGULATION 971
- 21.5 FACTOR ANALYSIS 972
- 21.6 RESEARCH ASSUMPTIONS 972
- 21.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT 973
- 22 APPENDIX 974
- 22.1 DISCUSSION GUIDE 974
- 22.2 KNOWLEDGESTORE: MARKETSDMARKETS' SUBSCRIPTION PORTAL 979
- 22.3 CUSTOMIZATION OPTIONS 981
- 22.4 RELATED REPORTS 981
- 22.5 AUTHOR DETAILS 982

Proteomics Market by Product (Spectroscopy, Chromatography, Electrophoresis, X-Ray Crystallography), Reagent, Service (Core Proteomics, Bioinformatics), Application (Diagnostic, Drug Discovery), End User (Hospital, Biopharma) - Global Forecast to 2030

Market Report | 2026-01-27 | 983 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

Zip Code*

Country*

Date

2026-06-09

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com